Track topics on Twitter Track topics that are important to you
XOMA is a leading biopharmaceutical company in the field of therapeutic antibody discovery and development. We have a royalty interest in one approved therapeutic antibody, RAPTIVA® (efalizumab), which is marketed in the United States, Europe and elsewhere, for the treatment of moderate-to-severe plaque psoriasis under an agreement with Genentech, Inc. as a result of a prior collaborative product development program. We also have royalty interests in additional therapeutic antibody product candidates being developed by others as a result of licensing our technologies. XOMA’s pipeline includes both proprietary products and collaborative programs at various stages of preclinical and clinical development primarily directed toward treatments for cancer and immune disorders. XOMA has contributed key innovations to the field of therapeutic antibodies. Today we possess an exceptionally broad technology platform for the discovery, optimization and manufacture of therapeutic antibodies as well as a fully integrated product development infrastructure for antibodies and other biologics.
2910 Seventh Street
United States of America
Phone: 510 204-7200
Fax: 510 644 2011
Novartis gained worldwide rights to commercialize Xoma's IL-1 beta mAb candidate gevokizumab, or XOMA 052, and a nonexclusive -More-
Shares of US biotech firm XOMA Corp closed up 24.3% at $11.10 on Friday, after the company revealed an…
Xoma Corp. licensed Novartis AG exclusive worldwide rights to gevokizumab (XOMA052), an anti-interleukin-1 beta (IL-1b) allosteric monoclonal antibody. Novartis also secured nonexclusive rights to Xom...
The big pharma will spend $31 million upfront and pay down part of Xoma's debt to gain access to the biotech's anti-inflammatory drug.
Xoma has licensed the global commercial rights to gevokizumab, a novel anti-IL-1 beta allosteric monoclonal antibody, to Novartis.
Xoma Corp. is selling Nanotherapeutics Inc. its biodefense business and related assets (including US government contracts).
The purpose of this study is to evaluate the safety and clinical pharmacology of a single dose of XOMA 358 in patients with hypoglycemia after gastric bypass surgery.
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of XOMA 052 in subjects with stable Type 2 Diabetes Mellitus (T2D). It is hypothesized that administration of...
The study hypothesis is that XOMA 052 improves glycemic control in subjects with Type 2 Diabetes. Study X052078 is designed to establish efficacious dose(s) for future studies based on ...
Study X052070 will evaluate the safety and pharmacokinetics (PK) of XOMA 052 administered to patients with active, stable, moderate to severe rheumatoid arthritis (RA). It is hypothesized...
The purpose of this study is to evaluate the safety and clinical pharmacology of a single dose pharmacokinetics and pharmacodynamics of XOMA 358 in subjects with hypoglycemia associated wi...
XOMA is a leading biopharmaceutical company in the field of therapeutic antibody discovery and development. We have a royalty interest in one approved therapeutic antibody, RAPTIVA® (efalizumab), whi...
We have published hundreds of XOMA news stories on BioPortfolio along with dozens of XOMA Clinical Trials and PubMed Articles about XOMA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of XOMA Companies in our database. You can also find out about relevant XOMA Drugs and Medications on this site too.
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Biocon Launches ALZUMAb™ - a ‘First in Class’ Novel Biologic Treatment for Psoriasis Patients in India • ALZUMAb™-World's first novel anti-CD6 antibody developed by Biocon to address a large unmet need for th...